Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.07T
Market cap1.07T
Price-Earnings ratio
38.60
Price-Earnings ratio38.60
Dividend yield
0.59%
Dividend yield0.59%
Average volume
2.20M
Average volume2.20M
High today
$1,151.23
High today$1,151.23
Low today
$1,132.63
Low today$1,132.63
Open price
$1,139.57
Open price$1,139.57
Volume
1.48M
Volume1.48M
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$712.05
52 Week low$712.05

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,137.00, giving the company a market capitalization of 1.07T. It carries a P/E multiple of 38.60 and pays a dividend yield of 0.59%.

On 2026-09-16, Eli Lilly(LLY) stock traded between a low of $1,132.63 and a high of $1,151.23. Shares are currently priced at $1,137.00, which is +0.4% above the low and -1.2% below the high.

The Eli Lilly(LLY)'s current trading volume is 1.48M, compared to an average daily volume of 2.2M.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

LLY News

Washington Post 16m
Health Brief: The fight over GLP-1 coverage - The Washington Post

...

Health Brief: The fight over GLP-1 coverage - The Washington Post
The Motley Fool 6h
Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?

Several years ago, Novo Nordisk (NVO -1.22%) -- which is now branding itself as Novo -- was performing so well that it was improving the entire economy of its h...

Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?
Investor's Business Daily 7h
Arista Stock Holds Up Well Amid Weakness. Here's How To Capitalize.

These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Cloudflare Hits Buy Point 9/16/2026 Among the best stocks in earnings performance, highly...

Arista Stock Holds Up Well Amid Weakness. Here's How To Capitalize.

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

Benzinga 7h
Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem

Twist Bioscience Corporation (NASDAQ:TWST) on Wednesday announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli...

Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem
TipRanks 10h
Twist Bioscience enters agreement with Lilly TuneLab

Twist Bioscience Corporation (TWST) announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (L...

Simply Wall St 16h
Eli Lilly Backs Nucleic Acid Research In Nervous System Diseases

Eli Lilly (NYSE: LLY) has entered a research and collaboration agreement with QurCan Therapeutics focused on nucleic acid therapies. The partnership targets ce...

Eli Lilly Backs Nucleic Acid Research In Nervous System Diseases
Nasdaq 1d
Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything

Key Points Eli Lilly's breakthroughs in its core therapeutic area are driving excellent financial results. The company could hit significant headwinds if it e...

Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything
24/7 Wall St. 1d
Novo Nordisk Expands Obesity Drug to Children, But Market Hesitates on Adoption

Investing Novo Nordisk Expands Obesity Drug to Children, But Market Hesitates on Adoption A landmark trial just proved semaglutide can pull children as young as...

Novo Nordisk Expands Obesity Drug to Children, But Market Hesitates on Adoption
Nasdaq 1d
Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson (Symbol: JNJ) is the #10 broker pick, on average, out of the 30 stocks m...

Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick
Seeking Alpha 1d
Eli Lilly boosted to Buy at Berenberg as upside to 2026 guidance seen

Berenberg upgraded Eli Lilly (LLY) to Buy from Hold, saying that it sees the drugmaker exceeding its 2026 guidance driven by continuing its lead in the weight-l...

Eli Lilly boosted to Buy at Berenberg as upside to 2026 guidance seen

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.